ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2020, 'Precision medicine for high-risk paediatric and AYA sarcomas', Lorne, presented at Lorne Cancer 2020, Lorne, 13 February 2020
,2019, 'Personalised medicine for high-risk paediatric and AYA sarcoma patients', Tokyo, Japan, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting, Tokyo, Japan, 13 November 2019, https://www.ctos.org/Portals/0/PDF/2019%20CTOS%20Final%20Program.pdf
,2019, 'Precision medicine for high-risk paediatric and AYA sarcomas', Sydney, presented at Kids Cancer Alliance - Annual Meeting, Sydney, 31 October 2019, https://kca.org.au/wp-content/uploads/2019/11/2019-ECR-and-Student-Event-Program.pdf
,2018, 'Synthetic lethality in synovial sarcoma: SS18-SSX fusions and DNA damage response (DDR) inhibitors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-2975
,2017, 'Phosphoproteomic landscape of sarcoma: novel subgroups and actionable targets', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-5837
,2013, 'Abstract 2761: Temsirolimus is effective as a single agent and in combination with cisplatin or bevacizumab in preclinical osteosarcoma models.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2761 - 2761, http://dx.doi.org/10.1158/1538-7445.am2013-2761
,2011, 'Abstract 5283: MicroSPECT imaging of IGF1R expression with radiolabeled R1507 in osteosarcoma models', in Cancer Research, American Association for Cancer Research (AACR), pp. 5283 - 5283, http://dx.doi.org/10.1158/1538-7445.am2011-5283
,2023, Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas, , http://dx.doi.org/10.1101/2023.07.19.548825
,2023, Precision-guided treatment improves outcomes for children with high-risk cancers, , http://dx.doi.org/10.21203/rs.3.rs-3376668/v1
,